<DOC>
	<DOCNO>NCT01551511</DOCNO>
	<brief_summary>Abdominal pain result chronic pancreatitis ( CP ) often recurrent , intense long-lasting , extremely difficult treat . Medical analgesic therapy consider first choice pain management CP , result regularly prescription opioids . The adverse consequence prolong opioid use , include addiction , tolerance opioid induce hyperalgesia , call alternative medical treatment . Cannabis use treat pain many century . Delta-9-tetrahydrocannabinol ( Δ9-THC ) , psychoactive substance cannabis plant , show previous study promise analgesic . The development Namisol® , tablet contain purify Δ9-THC showing improve pharmacokinetic profile , provide opportunity test analgesic potential Δ9-THC favourable condition . The current study aim investigate analgesic efficacy Namisol® add-on analgesic long-term treatment ( 52 day ) abdominal pain result CP .</brief_summary>
	<brief_title>Δ9-THC ( Namisol® ) Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Abdominal Pain</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Aged 18 year old Confirmed chronic pancreatitis Pain duration exceed 3 month , average NRS≥3 Stable dos intake analgesic past 2 month The patient inform study , understood information sign informed consent form Patient take cannabinoids regular basis least one year Patient feel pinprick test low extremity Patient body mass index ( BMI ) 32,0 kg/m2 Patient suffers serious painful condition chronic pancreatitis Patient significant medical disorder may interfere study may pose risk patient Patient use kind concomitant medication may interfere study may pose risk patient Patient tolerate oral intake medication liquid , refrain oral intake medical reason Patient demonstrate clinical relevant deviation electrocardiogram ( ECG ) Patient actual moderate severe renal impairment Patient actual moderate severe hepatic impairment Patient presence history major psychiatric illness Patient experience epileptic seizure past Patient demonstrate clinically significant laboratory abnormality Patient demonstrate positive urine drug screen THC , cocaine , MDMA , amphetamines Patient demonstrate positive test result hepatitis B surface antigen , hepatitis C antibody HIV antibody test Patient history sensitivity / idiosyncrasy THC Patient know suspect lactose intolerance Female patient pregnant breastfeeding Patient intend conceive child course study Patient participate another investigational drug study Patient clinical significant exacerbation illness Patient unwilling unable comply lifestyle guideline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>chronic pancreatitis</keyword>
	<keyword>abdominal pain</keyword>
	<keyword>visceral pain</keyword>
	<keyword>chronic pain</keyword>
</DOC>